Identifying the Highest Risk PAD Patients

Jul 22, 2022 | PAD

2) This educational program is accredited for 0.5h CE/#CME & is intended for healthcare professionals. Author disclosures & Accreditation Statement are at https://t.co/gvXca4G9Xm. Visit https://t.co/NOg9ub8H2q for previous programs for more credit! #FOAMed...

Evaluating Post-Intervention Treatment Options for PAD

Jun 28, 2022 | PAD

2) The @cardiomet_ce program is supported by educational grants from AstraZeneca, Bayer, Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly Company, Bristol Myers Squibb & its Alliance partner Pfizer Inc, Chiesi, & Esperion. This program is intended for...

Optimizing Outcomes in Patients with PAD after Revascularization

Jan 4, 2022 | PAD

2) The @cardiomet_ce program is supported by educational grants from AstraZeneca, Bayer, Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly Company, Bristol Myers Squibb & its Alliance partner Pfizer Inc, Chiesi, & Esperion. This program is intended for...

A Case-Based Program on Evidence-Based Management of PAD

Apr 15, 2021 | PAD

1) Welcome to our accredited tweetorial on #PAD ! Expert faculty @JoshuaBeckmanMD. Earn 0.5h CME/CE credit by following this thread. Supported by Abbott, AstraZeneca, Bayer, Chiesi, NovoNordisk. #cardiotwitter @MedTweetorials @GameofAcademics @CMichaelGibson—...